PSMB1

PSMB1 (proteasome subunit β6/C5) is a core component of the 20S proteasome that drives ubiquitin-proteasome-dependent degradation of specific regulatory substrates, and a p(Tyr103His) variant that weakens its interaction with the PSMA5/α5 subunit destabilizes the 20S complex, impairs PSMB1 processing and incorporation, and reduces proteasome activity (PMID:32129449). Beyond its structural role, PSMB1 selects defined substrates for destruction: it binds BCL-3 to mediate Lys48-polyubiquitin-dependent degradation independently of FBW7 (PMID:20558726), promotes proteasomal degradation of IKK-ε to negatively regulate RLR- and TLR3-driven antiviral signaling (PMID:30682859), and directly binds the oncoprotein RAB34 to promote its degradation and thereby inactivate MEK/ERK signaling and suppress colorectal cancer progression (PMID:38159835). PSMB1 also routes viral proteins for selective autophagy, recruiting the cargo receptor NBR1 to degrade PRRSV Nsp12 and restrict viral replication (PMID:36602366). Loss of psmb1 in zebrafish produces microcephaly, microphthalmia, and craniofacial cartilage, tendon, and muscle defects through both tissue-autonomous and non-autonomous mechanisms, establishing essential roles in proteasome assembly and in brain and craniofacial development (PMID:32129449, PMID:39171526). A distinct nuclear pool of PSMB1, regulated by tyrosine phosphorylation status, acts as a transcriptional activator of the Rbp4 gene in adipocytes (PMID:23924720).

1. 2010 High

   Established that PSMB1 is not merely a passive catalytic subunit but a substrate-selective docking point of the proteasome, recruiting a specific polyubiquitinated target for degradation.

   Evidence Yeast two-hybrid, co-IP, PSMB1 knockdown, and BCL-3 lysine mutagenesis in cultured cells

   PMID:20558726

   Open questions at the time

   • Does not define how PSMB1 distinguishes BCL-3 from other ubiquitinated proteins
   • Mechanism of recruitment to the catalytic core not structurally resolved
   • Generality of substrate-specific binding beyond BCL-3 not tested
2. 2012 Low

   Addressed whether PSMB1 is a direct drug target by testing small-molecule binding to recombinant protein.

   Evidence BIAcore surface plasmon resonance binding of recombinant PSMB1 to celastrol in vitro

   PMID:22667125

   Open questions at the time

   • Single in vitro binding assay with no functional follow-up
   • No demonstration that binding affects proteasome activity in cells
   • Binding site on PSMB1 not mapped
3. 2013 Medium

   Revealed a moonlighting nuclear function for PSMB1 as a transcriptional activator and showed its localization is controlled by tyrosine phosphorylation.

   Evidence Tyrosine-to-phenylalanine mutagenesis, nuclear translocation and transcriptional reporter assays in adipocytes

   PMID:23924720

   Open questions at the time

   • Kinase/phosphatase controlling the phosphorylation site not identified
   • Direct DNA or promoter binding by PSMB1 not demonstrated
   • Relationship between nuclear PSMB1 and assembled 20S proteasome unclear
4. 2019 Medium

   Connected PSMB1-mediated degradation to immune signaling by identifying IKK-ε as a substrate whose turnover dampens antiviral responses.

   Evidence Reciprocal co-IP, knockdown/overexpression, ISRE/IFNβ luciferase reporters, and proteasome inhibitor assays in viral infection models

   PMID:30682859

   Open questions at the time

   • E3 ligase ubiquitinating IKK-ε not identified
   • Single lab; reciprocal substrate-specificity controls limited
   • In vivo physiological relevance of antiviral regulation not tested
5. 2020 High

   Demonstrated the consequences of disrupting PSMB1 assembly, linking a missense variant to 20S destabilization and to developmental phenotypes in vivo.

   Evidence Structural modeling, proteasome activity/processing assays in SHSY5Y cells, and CRISPR/morpholino knockdown in zebrafish

   PMID:32129449

   Open questions at the time

   • No formal Mendelian disease gene attribution stated in the finding
   • Mechanism linking reduced proteasome activity to microcephaly not resolved
   • Whether substrate-specific functions are also impaired by the variant untested
6. 2023 Medium

   Extended PSMB1 substrate selection into autophagy, showing it can recruit a cargo receptor to route a viral protein for autophagic rather than proteasomal degradation.

   Evidence Co-IP, lysosomal co-localization, autophagy/proteasome inhibitor assays, and K130 mutagenesis of PRRSV Nsp12

   PMID:36602366

   Open questions at the time

   • How PSMB1 chooses autophagy versus proteasome routing unclear
   • Direct interaction with NBR1 versus indirect bridging not fully resolved
   • Single lab; host-protein substrates of this autophagy route not identified
7. 2023 Medium

   Showed PSMB1 substrate selection has tumor-suppressive output by degrading RAB34 to inactivate MEK/ERK signaling, and is pharmacologically enhanceable.

   Evidence Co-IP, proteasome-dependent degradation assays, MEK/ERK western blotting, PDX/liver metastasis mouse models, and kinetin drug screening

   PMID:38159835

   Open questions at the time

   • Structural basis of PSMB1–RAB34 binding not defined
   • Whether kinetin acts directly on PSMB1 not established
   • Generality across cancer types beyond colorectal not tested
8. 2024 Medium

   Defined the developmental tissue requirements for psmb1, distinguishing autonomous from non-autonomous roles in craniofacial morphogenesis.

   Evidence Zebrafish psmb1 mutant phenotyping with sox10+ cell-type-specific rescue and live imaging of chondrocyte behavior

   PMID:39171526

   Open questions at the time

   • Molecular substrates underlying chondrocyte/tendon/muscle defects unknown
   • Why muscle phenotype is only partially rescued unresolved
   • Link between proteasome activity and convergent extension mechanistically undefined

• How PSMB1 achieves substrate selectivity across distinct degradation routes (proteasomal versus autophagic) and how its catalytic/structural role integrates with its nuclear transcriptional and developmental functions remains unresolved.
• No structural model of PSMB1 substrate-binding interface
• Unifying mechanism connecting proteasome assembly, substrate selection, and nuclear function absent
• E3 ligases pairing with PSMB1 for most substrates unidentified